GlassScriptPhysician profile
Jalaja Piska
NPI 1427035815
$4,276.47
in general payments reported to CMS, 2019-2025
35 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $527 · 2021: $695 · 2022: $569 · 2023: $227 · 2024: $325 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428 · Travel and Lodging: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.55 |
| Travel and Lodging | $165.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $636.94 | 2019-2022 | |
| Nalu Medical, INC. | $472.88 | 2021-2025 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $467.00 | 2019-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $308.50 | 2019-2025 | Proclaim, Eterna |
| Abbvie INC. | $281.42 | 2022-2025 | |
| Si-Bone, INC. | $256.65 | 2020-2025 | |
| Boston Scientific Corporation | $207.30 | 2019-2024 | |
| Pacira Pharmaceuticals Incorporated | $192.11 | 2024-2025 | Iovera, Exparel, Zilretta |
| Amgen INC. | $186.16 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $165.72 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $148.83 | 2019-2021 | |
| Lilly USA, LLC | $140.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $138.75 | 2019-2021 | |
| Pfizer INC. | $77.70 | 2019-2023 | |
| Ibsa Pharma INC. | $69.18 | 2021-2023 | Tirosint, Licart |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $56.60 | 2024-2025 | Horizant |
| Almatica Pharma LLC | $52.16 | 2021-2023 | Gralise |
| Merck Sharp & Dohme LLC | $50.43 | 2023-2024 | Bridion, Dificid |
| Zyla Life Sciences, INC. | $32.92 | 2020 | |
| Assertio Therapeutics, INC. | $29.75 | 2019 | |
| Vertos Medical, INC. | $29.55 | 2023-2024 | Mild Device Kit |
| Redhill Biopharma INC. | $27.73 | 2021 | |
| Nevro Corp. | $26.16 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $25.07 | 2019 | |
| Horizon Therapeutics Plc | $23.78 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $23.50 | 2025 | |
| Bioventus LLC | $20.49 | 2022 | |
| Saluda Medical Americas, INC. | $19.05 | 2022 | |
| Depuy Synthes Sales INC. | $18.74 | 2024 | Monovisc |
| Daiichi Sankyo INC. | $18.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.79 | 2025 | Relistor |
| Fisher & Paykel Healthcare INC | $15.50 | 2024 | Fisher & Paykel Healthcare |
| Electronic Waveform Lab, INC. | $15.02 | 2019 | |
| Foundation Fusion Solutions, LLC | $13.80 | 2025 | |
| Relievant Medsystems, INC. | $10.36 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jalaja Piska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.